Stay updated on EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial
Sign up to get notified when there's something new on the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page.

Latest updates to the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check40 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check55 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has updated the type of intervention and the age range to '18 Years to 100 Years', with the latest revision now at v2.14.0, while removing previous entries related to '18 Years and older' and the earlier revision v2.13.3.SummaryDifference1%
- Check91 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page.